However, the advent of ICIs (immune checkpoint inhibitors), including PD-1 (inhibitors of programmed cell death protein 1) and PD-L1 (programmed death-ligand 1), in the therapeutic landscape of this aggressive tumor started to change the outcome of patients with ED-SCLC. This evidence concerns the gene PDCD1 and small cell lung carcinoma.